First-of-its-Kind gene therapy injected into spine to fight Alzheimer's
NCT ID NCT03634007
Summary
This early-stage study tested the safety of a new gene therapy, LX1001, for people with Alzheimer's disease who carry a specific genetic risk factor (two copies of the APOE4 gene). The therapy was injected into the spinal fluid of 15 participants over a year to see if it was safe and to find the right dose. The goal was to see if the treatment could change a key protein in the brain linked to Alzheimer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27708, United States
-
K2 Medical Research
Maitland, Florida, 32751, United States
-
PPD- Orlando Research Unit
Orlando, Florida, 32806, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.